​

Marinus Pharmaceuticals (MRNS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MRNS Stock Forecast

Marinus Pharmaceuticals (MRNS) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $3.67, with a high of $6.00 and a low of $2.00. This represents a 567.27% increase from the last price of $0.55.

- $3 $6 $9 $12 $15 High: $6 Avg: $3.67 Low: $2 Last Closed Price: $0.55

MRNS Stock Rating

Marinus Pharmaceuticals stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (52.94%), 8 Hold (47.06%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 8 9 Strong Sell Sell Hold Buy Strong Buy

MRNS Price Target Upside V Benchmarks

TypeNameUpside
StockMarinus Pharmaceuticals567.27%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$6.00
Last Closing Price$0.55$0.55$0.55
Upside/Downside--990.91%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25-16--7
Jan, 25-16--7
Dec, 24-27--9
Nov, 24-37--10
Oct, 24277--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 23, 2024Jay OlsonOppenheimer$6.00$1.67259.28%990.91%
Apr 16, 2024Brian SkorneyRobert W. Baird$2.00$1.3053.85%263.64%
Apr 15, 2024Sector PerformRBC Capital$3.00$1.42111.27%445.45%
Mar 28, 2024Jay OlsonOppenheimer$9.00$9.04-0.44%1536.36%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2024JMP SecuritiesMarket Performdowngrade
Sep 23, 2024Cowen & Co.BuyBuyhold
Sep 23, 2024OppenheimerUnderperformOutperformupgrade
Aug 14, 2024Cowen & Co.BuyBuyhold
May 07, 2024OppenheimerUnderperformUnderperformhold
Apr 16, 2024RBC CapitalSector PerformSector Performhold
Apr 16, 2024Cantor FitzgeraldOverweightOverweighthold
Apr 15, 2024RBC CapitalOutperformSector Performdowngrade
Mar 28, 2024OppenheimerPerformPerformhold
Mar 08, 2023RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.44$-2.77$-0.51------
Avg Forecast$-2.45$-2.68$-0.34$-2.52$-2.06$-0.50$-0.21$0.06$0.39
High Forecast$-1.38$-1.51$-0.20$-2.40$-1.98$-0.25$0.06$0.18$0.50
Low Forecast$-3.88$-4.24$-0.44$-2.58$-2.14$-0.76$-0.35$-0.05$0.33
Surprise %-0.41%3.36%50.00%------

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.72M$15.35M$25.48M$30.99M-----
Avg Forecast$1.37M$17.03M$27.71M$31.80M$34.87M$55.41M$61.31M$81.37M$104.64M
High Forecast$1.98M$24.63M$33.92M$33.54M$41.88M$60.99M$75.53M$100.24M$128.92M
Low Forecast$904.83K$11.28M$18.67M$30.74M$32.27M$52.36M$54.34M$72.12M$92.75M
Surprise %25.78%-9.89%-8.07%-2.54%-----

Net Income Forecast

$-250M $-190M $-130M $-70M $-10M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-66.64M$-101.66M$-19.82M$-144.48M-----
Avg Forecast$-131.84M$-144.15M$-18.32M$-133.80M$-110.70M$-39.60M$-18.33M$8.11M$20.71M
High Forecast$-73.99M$-80.89M$-10.55M$-129.19M$-106.60M$-13.67M$3.44M$9.59M$26.95M
Low Forecast$-208.37M$-227.82M$-23.65M$-138.42M$-114.80M$-41.00M$-18.57M$-2.88M$17.65M
Surprise %-49.45%-29.48%8.15%7.98%-----

MRNS Forecast FAQ

Is Marinus Pharmaceuticals stock a buy?

Marinus Pharmaceuticals stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 8 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Marinus Pharmaceuticals is a favorable investment for most analysts.

What is Marinus Pharmaceuticals's price target?

Marinus Pharmaceuticals's price target, set by 17 Wall Street analysts, averages $3.67 over the next 12 months. The price target range spans from $2 at the low end to $6 at the high end, suggesting a potential 567.27% change from the previous closing price of $0.55.

How does Marinus Pharmaceuticals stock forecast compare to its benchmarks?

Marinus Pharmaceuticals's stock forecast shows a 567.27% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Marinus Pharmaceuticals over the past three months?

  • February 2025: 0% Strong Buy, 14.29% Buy, 85.71% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 0% Strong Buy, 14.29% Buy, 85.71% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 0% Strong Buy, 22.22% Buy, 77.78% Hold, 0% Sell, 0% Strong Sell.

What is Marinus Pharmaceuticals’s EPS forecast?

Marinus Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2024 is $-2.06, marking a 0% decrease from the reported $0 in 2023. Estimates for the following years are $-0.5 in 2025, $-0.21 in 2026, $0.06 in 2027, and $0.39 in 2028.

What is Marinus Pharmaceuticals’s revenue forecast?

Marinus Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2024 is $34.87M, reflecting a 12.52% increase from the reported $30.99M in 2023. The forecast for 2025 is $55.41M, followed by $61.31M for 2026, $81.37M for 2027, and $104.64M for 2028.

What is Marinus Pharmaceuticals’s net income forecast?

Marinus Pharmaceuticals's net income forecast for the fiscal year ending in December 2024 stands at $-111M, representing a -23.38% decrease from the reported $-144M in 2023. Projections indicate $-39.599M in 2025, $-18.326M in 2026, $8.11M in 2027, and $20.71M in 2028.